Skip to main content
Clinical Trials/NCT03736629
NCT03736629
Terminated
Phase 2

The AZITRAMBA Trial: Azithromycin Treatment for the Airway Microbiome in Asthma

University of Chicago2 sites in 1 country17 target enrollmentFebruary 1, 2019

Overview

Phase
Phase 2
Intervention
Placebo
Conditions
Asthma Chronic
Sponsor
University of Chicago
Enrollment
17
Locations
2
Primary Endpoint
Asthma Control Test (ACT) Score Change From Baseline Over 8 Weeks
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study to determine whether the bacteria inside the lungs of people with asthma can be modified (changed) if they are given an antibiotic and if this change is associated with an improvement in asthma symptoms.

Registry
clinicaltrials.gov
Start Date
February 1, 2019
End Date
June 1, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Placebo

8 weeks of placebo capsule once daily by mouth

Intervention: Placebo

Azithromycin

8 weeks of Azithromycin (250 mg) capsule once daily by mouth

Intervention: Azithromycin

Outcomes

Primary Outcomes

Asthma Control Test (ACT) Score Change From Baseline Over 8 Weeks

Time Frame: Baseline and 8 weeks

Score ranging from 0 to 40 indicating the degree of asthma symptoms. Lower score indicating worse asthma symptoms.

Secondary Outcomes

  • Forced Expiratory Volume (FEV1) Change From Baseline Over 8 Weeks(8 weeks)
  • Sputum Eosinophils Change From Baseline Over 8 Weeks(Baseline and 8 weeks)
  • Sputum Neutrophils Change From Baseline Over 8 Weeks(Baseline and 8 weeks)
  • Number of Participants With Diary Event or Serious Asthma Exacerbation Over 8 Weeks(8 weeks)
  • Microbiome Shannon Alpha-diversity Score Change From Baseline to 8 Weeks(8 weeks)
  • Microbiome Beta-diversity Score Change From Baseline to 8 Weeks(8 weeks)
  • Microbiome Change in Relative Proportion of Top 10 Genera From Baseline to 8 Weeks(8 weeks)

Study Sites (2)

Loading locations...

Similar Trials